Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
Status:
Terminated
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This is a study in which pancreatic cancer patients receive a combination therapy with
CART-meso cells and CART19 cells administered at 3 days after one dose of cyclophosphamide.
CART-meso cells are patients' own T cells that were modified in the laboratory to express a
receptor specific to the mesothelin protein. CART19 cells are patients' own T cells that were
modified in the laboratory to express a receptor specific to a protein called CD19. The CD19
protein is expressed on white blood B cells. CART19 cells are expected to attack the B cells
and impede the antibody response against CART-meso cells. The investigators hypothesize that
this combination therapy may prolong the duration of CART-meso cells in the body.
Additionally, one dose of cyclophosphamide may enhance engraftment and persistence of CART
cells.